Sirolimus, Trastuzumab Well-Tolerated in Breast Cancer Progression with Prior Therapy

Share this content:
Combination sirolimus and trastuzumab is well-tolerated in metastatic HER2-positive breast cancer after disease progression.
Combination sirolimus and trastuzumab is well-tolerated in metastatic HER2-positive breast cancer after disease progression.

Combination sirolimus and trastuzumab is well-tolerated in patients with metastatic human epidermal growth factor receptor  (HER2)-positive breast cancer after disease progression with prior trastuzumab therapy, according to a study published in Breast Cancer Research and Treatment.

In a phase II trial, researchers led by Carlos Acevedo-Gadea, MD, of the Yale University School of Medicine administered sirolimus 6 mg oral daily along with a standard dose of trastuzumab weekly or every three weeks.

In total, eleven patients were evaluated for safety, and nine were evaluated for response assessment.

RELATED: Paclitaxel, Trastuzumab New Standard of Care for Early-Stage Breast Cancer

They found that five patients who were treated for 101 weeks had achieved stable disease as best response, while one patient who received eight cycles achieved a partial response.

Overall response rate amounted to 11 percent while clinical benefit rate was 44%.

“Sirolimus 6 mg administered daily with trastuzumab appears to be well-tolerated in patients with metastatic HER2-positive breast cancer following disease progression on prior trastuzumab therapy, with evidence of disease activity,” the authors concluded.

Reference

  1. Acevedo-Gadea, Carlos. "Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy." Breast Cancer Research and Treatment. DOI: 10.1007/s10549-015-3292-8. February 17, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters